Condition: High-Risk Neuroblastoma · Patient With Insufficient Response Chemoimmunotherapy · Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.
This description comes directly from the study's public registry record.
Claudia Pasqualini, MD PhD · +33 (0)1 42 11 42 11 · claudia.pasqualini@gustaveroussy.fr
Habiba Attalah, PhD · +33 (0)1 42 11 64 46 · habiba.attalah@gustaveroussy.fr
Always discuss trial participation with your own doctor first.
| Sydney children Hospital | Sydney, Randwick, Australia | Recruiting |
| Children's Cancer Centre, Monash Children's Hospital | Clayton, Australia | Recruiting |
| Oncology/Haematology Department, Perth Children's Hospital | Nedlands, Australia | Suspended |
| Children's Cancer & Haematology Services, John Hunter Children's Hospital | New Lambton Heights, Australia | Recruiting |
| Australian and New Zealand Children's Hematology/oncology Group | Sydney, Australia | Active Not Recruiting |
| sydney children Hospital | Sydney, Australia | Recruiting |
| Cancer Centre for Children, The Children's Hospital | Westmead, Australia | Suspended |
| Medical University Graz | Graz, Austria | Recruiting |
| Landeskrankenhaus-Universitätsklinikum Innsbruck | Innsbruck, Austria | Recruiting |
| Kepler Universitatsklinikum Linz | Linz, Austria | Recruiting |
| Universitastsklinikum Salzburg | Salzburg, Austria | Recruiting |
| St Anna'S Children Hospital | Vienna, Austria | Recruiting |
+ 130 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04221035